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ABSTRACT 
Glioblastomas are the most common malignant brain tumor, with an annual incidence of 
6 in 100,000 people. Conventional treatment modalities, including chemotherapy and 
radiation, are toxic and cause a decrease in quality of life as the disease progresses. 
Several investigators have turned to pharmacologically active derivatives of herbal 
remedies as less-toxic alternatives. Indirubin, a dark red isomer of indigo, is known to be 
effective in treating chronic inflammation and some forms of cancer, and the mechanism 
is, in part, due to activity as a ligand for the transcription factor aryl hydrocarbon receptor 
(AhR). As with most AhR ligands, indirubin induces the CYP1 family of metabolizing 
enzymes, alters cell cycling, and can be active through the GSK-3β pathway. In recent 
years, bioavailable derivatives have been synthesized, including indirubin-3’-(2,3 
dihydroxy-propyl)-oximether (E804). Several lines of research show that E804 has anti-
angiogenic and anti-proliferative properties, and we previously demonstrated anti-
inflammatory properties of E804. In this study, T98G human glioblastoma cells were 
treated with E804 to determine the degree of AhR activation, the secretion of both 
immunosuppressive and pro-inflammatory cytokines by the tumor cells, and the effects of 
those tumor secretions on macrophage polarization. E804 is potent inducer of CYP1B1 in 
T98G cells, has modest effects on TGFβ2 secretion, and suppresses VEGF at high does, 
while enhancing VEGF secretion at low doses. The secretion of IL-6 by T98G cells was 
only modestly affected at the highest treatment levels. The effects of supernatants derived 
from E804-treated T98G cells on macrophage indicate that E804 may polarize 
macrophages to the pro-tumor M2 phenotype. Overall, the results of this study indicate 
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that E804 concentrations would need to be carefully monitored in a clinical application. 
Future studies should include an in vivo model of brain tumors to test the potential of 
E804 as a standalone, or adjuvant treatment for glioblastoma. 
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CHAPTER ONE 
LITERATURE REVIEW 
BRAIN TUMORS AND CURRENT TREATMENT MODALITIES 
Brain tumors are among the most dreaded diagnosis in oncology. Brain and 
central nervous system cancers are the number one cause of cancer-related death in 
children 0-14, and the third leading cause in adolescents 15-19 according to the National 
Center for Health Statistics for 2014 (SEER, 2010). In general, prognosis is poor and 
there are few treatment options.  Tumors that originate in the brain are similar to other 
cancers in many ways, but also provide their own unique challenges. All cancer cells 
possess certain key traits: sustained growth signals, evasion of growth suppressors, 
activation of invasion and metastasis, induction of angiogenesis, resistance to cell death, 
evasion of the immune system, and the dysregulation of cellular energetics (as reviewed 
by (Hanahan and Weinberg, 2011). However, brain tumors are especially difficult for 
patients and care providers to manage (Schwartzbaum et al., 2006). Depending on the 
location and size of the tumor, patients can experience personality and mood shifts, 
severe headaches, seizures, and loss of senses, memory, coordination or bodily control 
(SEER, 2010). These symptoms are compounded by the fact that the brain is enclosed in 
a hard shell, the skull. Growth of tissue in one area can cause pressure and swelling of 
other areas, pushing against the skull, causing severe pain and even brain damage (Figure 
1). Tumors within the brain are also inherently more difficult to treat (Schwartzbaum et 
al., 2006). Surgery is not always an option due to the location of the tumor, but even if it 
is possible, there are many risks involved, including damage to other areas of the brain 
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(Omuro, 2013; Schwartzbaum et al., 2006). Radiation treatment can also quickly damage 
healthy regions. Chemotherapeutic drugs must be able to access the tumor, which can be 
challenging if the blood-brain barrier is still intact (Schneider et al., 2004). Brain tumors 
also tend to be more chemo-resistant than other forms of cancer (Adams et al., 2012). In 
this way, brain tumors, particularly rapidly growing types, such as glioblastoma, have the 
ability to completely incapacitate an individual. 
Glioblastoma (WHO grade IV) is a highly malignant, lethal form of brain cancer. 
Glioblastomas are the most common form of gliomas, which account for approximately 
80% of malignant brain tumors (Schwartzbaum et al., 2006), but their precise causes 
remain unknown. Glioblastomas are composed of a mixture of astrocytes, supportive 
star-shaped cells in the central nervous system, and endothelial cells (Omuro, 2013). 
Secondary finger-like structures are usually found away from the primary tumor (Paw et 
al., 2015). Tumor cells are capable of traveling down myelinated nerves and following 
the basement membrane of blood vessels, particularly within Virchow-Robins spaces 
(Pedersen et al., 1995). Virchow-Robins spaces are part of the subarachnoid and sub-pial 
space below the meninges which surround blood vessels that enter the brain (Pedersen et 
al., 1995). In these areas, the hydrostatic pressure of cerebral spinal fluid allows cells to 
move quickly, spreading far beyond the primary tumor (Pedersen et al., 1995). This 
invasive growth pattern makes glioblastomas nearly impossible to completely remove 
surgically (Giese, 2003). However, current treatment modalities usually begin with 
surgical removal of the majority of the tumor to relieve pressure on the surrounding 
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tissue, if the tumor is in an operable location. This also allows for more precise 
histological grading of the tumor (Omuro, 2013).  
 Following resection, first line treatments involve radiation therapy, chemotherapy, 
or a combination of the two. In glioblastoma and other progressed brain tumors, the blood 
brain barrier is often degraded, letting drugs more freely access the central nervous 
system (Schneider et al., 2004). Common chemotherapy agents include the DNA 
alkylating agents temozolomide (TMZ), carmustine, and lomustine (Omuro, 2013). After 
surgical removal of the majority of the tumor, carmustine-loaded chips called Gliadel® 
wafers can be implanted directly into the brain (Perry, 2007). These drugs, like all 
chemotherapy, are toxic and can have severe side effects, including impaired immune 
system function, nausea, vomiting, hypertension, and hematologic toxicity, such as 
anemia (Omuro, 2013; Perry, 2007). Newer treatments include a monoclonal antibody 
against vascular endothelial growth factor (VEGF) called bevacizumab (Avastin®) 
(Reardon et al., 2014). Bevacizumab inhibits angiogenesis, reducing the tumor’s ability 
to grow new blood vessels, limiting its size (Reardon et al., 2014). However, this 
treatment could also lead to hypertension, wound healing delays, venous or arterial 
thrombosis, and hematologic toxicity, among other side effects (Omuro, 2013; Reardon et 
al., 2014). With treatment, median 2 year survival rate for glioblastoma patients remains 
between approximately 2-30%, depending on age at diagnosis (Schwartzbaum et al., 
2006). Clearly, less toxic, more effective treatments are needed. For these alternatives, 
many researchers are looking to natural sources. 
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Figure 1: WHO grade IV glioma, American Journal of Neuroradiology, submitted by 
Jason McKellop, Amir Paydar, Girish Fatterpekar, Alexander Baxter, NYU Langone 
Medical Center, New York, NY. http://www.ajnr.org/site/com/2012jun.xhtml 
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INDIRUBINS AND THE ARYL HYDROCARBON RECEPTOR 
 Medicinal herbs and plants have been used for centuries to treat various ailments, 
including cancer. One such Chinese remedy is Danggui Longhui Wan, a mixture of 11 
herbs used to treat chronic myelocytic leukemia and other inflammatory diseases 
(Hoessel et al., 1999). After extensive research, the active compound in Danggui Longhui 
Wan was found to be a red isomer of the blue dye indigo, called indirubin (Hoessel et al., 
1999). Indirubin has been shown to slow or stop cell proliferation by inducing cell cycle 
arrest and apoptosis via cyclin dependent kinases (CDKs) (Hoessel et al., 1999) and 
glycogen synthase kinase-3β (GSK-3β) (Xie et al., 2004). Naturally occurring indirubin 
is not very bioavailable, so researchers have synthesized artificial indirubin derivatives 
(Moon et al., 2006). These derivatives vary in in the location and composition of their 
side chains, which alter their receptor binding affinity and, therefore, their downstream 
effects (Moon et al., 2006). One such derivative is indirubin-3’-(2,3 dihydroxypropyl)-
oximether (E804). E804 has been shown inhibit STAT3 and induce apoptosis in multiple 
human cancer cell lines (Nam et al., 2005b). E804 also has strong anti-inflammatory and 
anti-angiogenic properties, but the precise mechanism of this action remains unclear 
(Anderson, 2014; Chan et al., 2012). One known pathway is through interaction with the 
aryl hydrocarbon receptor.  
 The aryl hydrocarbon receptor (AhR), a transcription factor of the family helix-
loop-helix, has been heavily studied since its link to 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) toxicity in the 1970’s (Poland, 1976). The activation of AhR has been linked to 
several pathways, ranging from carcinogenesis (Andersson et al., 2002) to tumor 
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therapies (Koliopanos et al., 2002), depending on the strength of the ligand binding. The 
stronger the binding of a ligand to the AhR, the more toxic and long lasting its effects 
seem to be. Indirubins have been shown to interact with AhR in varying degrees 
(Knockaert et al., 2004), but their interactions are brief due to the compounds’ 
metabolism by cytochrome P450 enzymes like CYP1A1 and CYP1B1 (Spink et al., 
2003). Thus, indirubins that bind strongly, but transiently, to AhR may have potent anti-
inflammatory and anti-tumor properties without the side effects of more stable ligands 
like TCDD (Chan et al., 2012; Knockaert et al., 2004).  
 
INFLAMMATION AND IMMUNE RESPONSE 
 Inflammation is a complex bodily response to tissue damage or pathogen 
intrusion. Local acute inflammation is beneficial in destroying these invaders, but a 
chronic or inappropriate inflammatory response can damage healthy tissue and cause 
severe pain (Coussens and Werb, 2002). Chronic inflammation has also been shown to 
contribute to many aspects of cancer initiation, promotion, and metastasis (Coussens and 
Werb, 2002). After an injury occurs, damaged cells release chemokines that attract 
monocytes, which differentiate into macrophages in tissue, and aid in wound repair 
(Coussens and Werb, 2002). Similarly, when a tumor begins to form, the transformed 
glial cells release chemokines that activate and attract immune cells from within the CNS, 
called microglia, and macrophages from outside the CNS (Bingle et al., 2002; Ransohoff 
et al., 2015). However, rather than destroying the cancerous cells, the macrophages’ 
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function is suppressed within the tumor microenvironment (Kennedy et al., 2013). These 
tumor-associated macrophages and microglia (TAMs) quickly accumulate, and can 
compose 30 to 40 percent of the tumor’s volume (Kennedy et al., 2009). It has also been 
shown that the number of infiltrating macrophages positively correlates with the 
histological grade of the tumor (Nishie et al., 1999). 
There are two main lineages of TAMs; M1, which are inflammatory and capable 
of killing cancer cells, and M2, which suppress immune function (Kennedy et al., 2013). 
The M1 versus M2 phenotype can be distinguished through genetic and cytokine 
secretion profiling (Kennedy et al., 2013). M2 type TAMs are thought to suppress 
inflammation though interleukin 10 (IL-10) and transforming growth factor beta (TGF-β) 
secretion (Mantovani et al., 2002). Interleukin-6 (IL-6) has been shown to have both pro- 
and anti-inflammatory properties, as well as being implicated in increased angiogenesis 
and tumor metastasis (Liu et al., 2010). The M2 divergence also leads to increased VEGF 
release from tumor cells (Kennedy et al., 2013). During this progression, the tumor cells 
are releasing their own cytokines and growth factors, which can equal or exceed those 
produced by activated macrophages (Ulvestad et al., 1994). Interplay between the TAMs 
and tumor cells is also seen, which can feed each other’s secretion in a paracrine and 
autocrine method (Kennedy et al., 2013). Other proteins can also effect M1 versus M2 
polarization, such as arginase 1 and 2 (ARG1, ARG2), indoleamine 2,3-dioxygenase 1 
(IDO1), cyclooxygenase-2 (COX-2) (Barksdale et al., 2004; Iachininoto et al., 2013; Ino 
et al., 2013; Mellor and Munn, 2004). 
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The enzyme arginase catalyzes hydrolysis of L-arginine to L-ornithine and urea 
(Barksdale et al., 2004). There are two isomers of arginase, ARG1 and ARG2 (Bronte et 
al., 2003; Ino et al., 2013). Depletion of arginine within a given environment can reduce 
the expression of the CD3 ζ chain on cytotoxic (CD8+) T-cells, preventing the T-cell 
receptor from interacting with the major histocompatibility complex (MHC), resulting in 
T-cell anergy (Zea et al., 2005). Arginine is also necessary for nitric oxide (NO) 
synthesis, which is required for proper T-cell function (Barksdale et al., 2004). Increased 
ARG1 activity is one of the most well-defined markers of M2 polarization in mice, but 
ARG1 is only found in granulocytes in humans (Sica and Bronte). It has been shown that 
renal carcinoma granulocytes in humans may be acting through a similar mechanism as 
M2-polarized macrophages (Zea et al., 2005). ARG1 is also known to be induced by 
TGF-β, another cytokine implicated in immune suppression (Bodmer et al., 1989; Bronte 
et al., 2003). Alternatively, ARG2 is found in the mitochondria of most human cells, 
including monocytes. ARG2 is involved in the synthesis of polyamines and has been 
shown to be induced by IL-10 (Barksdale et al., 2004). Increased levels of ARG2 has 
been seen in macrophages isolated from patients with multiple sclerosis (MS) (Barksdale 
et al., 2004). However, linkage to cancer progression and severity depends on tissue type 
(Ino et al., 2013; Rotondo et al., 2008). Increased ARG2 expression has been found to 
correlate with poor prognosis in patients with pancreatic or prostate cancer, but not lung 
cancer (Ino et al., 2013; Rotondo et al., 2008).  
The enzyme IDO1 is responsible for the breakdown of L-tryptophan to 
kynurenines (KYN) (Iachininoto et al., 2013). An increase in KYN within a 
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microenvironment promotes FoxP3
+
 regulatory T-cell (Treg) activity, suppressing T-cell 
and dendritic cell responses (Iachininoto et al., 2013; Mellor and Munn, 2004). High 
levels of IDO1 has also been correlated with poor prognosis in patients with acute 
myeloid leukemia and certain solid tumors (Chamuleau et al., 2008). COX-2 is one of the 
two isoforms of the cyclooxygenase enzyme responsible for prostaglandin synthesis 
(Iachininoto et al., 2013; Minghetti, 2004). COX-2 is also a main cause of inflammation-
associated pain in the central nervous system, and the target of non-steroidal anti-
inflammatory drugs (NSAIDs) (Minghetti, 2004; Samad et al., 2001; Wang and DuBois, 
2009). Inhibition of COX-2 activity has been shown to suppress the activity Treg cells, 
promoting the destruction of lung cancer cells (Sharma et al., 2005). Both IDO1 and 
COX-2 are produced by human macrophages, and induced by interferon gamma (IFN-γ), 
which has been implicated in both pro- and anti-tumor pathways (Iachininoto et al., 2013; 
Zaidi and Merlino, 2011). 
 The understanding of the cytokine and growth factor profile of a given tumor is 
critical to proper treatment, and can shape the approach taken, particularly when 
considering immunotherapy (Reardon et al., 2014; Zea et al., 2005). The particularly 
immunosuppressive nature of the glioblastoma microenvironment has been cited as the 
source of struggle in the development of successful immune therapies, but recent 
advances have shown promise (Reardon et al., 2014). There are currently many clinical 
trials being conducted on immunotherapeutic options, including combinations of 
traditional chemotherapies with monoclonal antibodies, such as ipilimumab and 
tremilimumab (Reardon et al., 2014). 
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CHAPTER TWO 
EFFECTS OF THE INDIRUBIN DERIVATIVE E804 ON GLIOBLASTOMA 
ASSOCIATED IMMUNOMODULATION 
INTRODUCTION 
 Because of their location and quick growth, brain and central nervous system 
tumors are among the most difficult to treat and lethal types of cancer (SEER, 2010). The 
most common malignant brain tumor, glioblastoma, is highly invasive, rapidly growing, 
and impossible to completely remove by surgery alone (Giese, 2003; Holland, 2000; 
Omuro, 2013; SEER, 2010). As a result, these tumors must be treated in other ways, such 
as radiation and chemotherapy (Holland, 2000; Perry, 2007; Schwartzbaum et al., 2006). 
However, commonly used chemotherapeutic drugs like the DNA alkylating agents 
carmustine (BCNU), lomustine (CCNU), and temozolomide (TMZ) have severe side 
effects, including impaired immune system function, nausea, vomiting, hypertension, and 
hematologic toxicity, such as anemia (Newlands et al., 1997; Omuro, 2013; Ransohoff et 
al., 2015; Shinkaruk et al., 2003; Xiao and Link, 1998). 
To improve anti-tumor treatment options, scientists are exploring natural 
alternatives as treatments or adjuvants (Blažević et al., 2015; Chan et al., 2012; Choi et 
al., 2010; Heshmati et al., 2013a; Ichimaru et al., 2015). One natural compound, 
indirubin, is the main active ingredient in Danggui Longhui Wan, a Chinese herbal 
remedy used to treat chronic myelocytic leukemia and other inflammatory diseases 
(Blažević et al., 2015; Hoessel et al., 1999; Jakobs et al., 2005; Xiao et al., 2002). Natural 
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indirubin is isolated from the indigo plant, and is not very bioavailable because of its low 
solubility and absorption (Blažević et al., 2015; Chan et al., 2012; Hoessel et al., 1999). 
To improve bioavailability, synthetic indirubin derivatives have been synthesized 
(Blažević et al., 2015; Choi et al., 2010; Heshmati et al., 2013a; Kim et al., 2011; 
Polychronopoulos et al., 2004; Ribas et al., 2006). Most indirubins are thought to act 
mechanistically through the aryl hydrocarbon receptor (AhR), a ligand activated 
transcription factor and member of the basic-helix-basic loop pers-arnt-sims superfamily 
of proteins involved in environmental sensing, cell cycle regulation, circadian rhythms, 
and xenobiotic metabolism.  One of the most characterized activities, and a sensitive 
marker of the AhR activation, is the inductionof CYP1 family of xenobiotic metabolizing 
enzyme systems associated with Phase I, II, and III processing of environmental 
contaminants and endogenous ligands (Nebert et al., 2000).   AhR activation has been 
linked to a variety of effects, ranging from carcinogenic to chemotherapeutic, depending 
on the binding strength of the ligand (Andersson et al., 2002; Koliopanos et al., 2002).  
All cancer cells possess key traits in common: sustained growth signals, evasion 
of growth suppressors, activation of invasion and metastasis, induction of angiogenesis, 
resistance to cell death, evasion of the immune system, and the dysregulation of cellular 
energetics (as reviewed by (Hanahan and Weinberg, 2011). One of the most important 
aspects for the persistence of solid tumors, like glioblastoma, is the induction of 
angiogenesis to promote neo-vascularization to allow blood and nutrient flow to the 
otherwise hypoxic tumor center (Byrne et al., 2005; Carmeliet, 2005; Omuro, 2013). 
Immune cells and their secreted products play a large role in angiogenesis in tumors, 
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much like the process seen in wound healing (Carmeliet, 2005; Coussens and Werb, 
2002).  
  Glioblastoma patients are known to be immunocompromised in several ways 
(Bodmer et al., 1989; Chamuleau et al., 2008; Ino et al., 2013; Kennedy et al., 2009; 
Nishie et al., 1999; Paw et al., 2015; Ransohoff et al., 2015; Roy et al., 2014; Ryuto et al., 
1996; Sharma et al., 2005; Sica and Bronte; Ulvestad et al., 1994; Xiao and Link, 1998). 
Immunosuppression due to increased regulatory T cells, anti-inflammatory cytokine 
production, and decreased cytotoxic T cell activity in the tumor microenvironment has 
been well documented, and is known to contribute to tumor growth and metastasis 
(Bodmer et al., 1989; Letterio, 1998; Ransohoff et al., 2015; Reardon et al., 2014). 
Because of this, immunotherapeutic treatment targets are currently being researched 
(Kennedy et al., 2009; Mantovani et al., 2002; Nishie et al., 1999; Ransohoff et al., 2015; 
Reardon et al., 2014; Sharma et al., 2005; Sica and Bronte; Ulvestad et al., 1994). One 
area of interest is the polarization of macrophages and microglia, macrophage-like cells 
in the CNS, to M1 or M2 phenotypes within the tumor (Mantovani et al., 2002; Nakanishi 
et al., 2011; Nishie et al., 1999; Zea et al., 2005). M1 macrophages are classical 
inflammatory immune cells that can actively suppress tumor cell growth through 
secretion of pro-inflammatory cytokines, while M2 macrophages support tumor growth 
by secreting anti-inflammatory cytokines and hindering cytotoxic T cell activity by 
increasing regulatory T cell presence and downregulating antigen presentation (Kennedy 
et al., 2013; Mantovani et al., 2002; Sica and Bronte; Wu et al., 2010).  
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Polarization of macrophages to M1 versus M2 can be measured in their gene 
expression (Mantovani et al., 2002). Prior studies have identified increased ARG2 and 
IL-6 as M1 macrophages markers, and ARG1, IDO1, and IL-10 as M2 macrophage 
markers (Bronte et al., 2003; Ino et al., 2013; Mantovani et al., 2002; Nakanishi et al., 
2011; Sharma et al., 2005; Zea et al., 2005). COX-2 has been suggested as a marker for 
both M1 and M2 macrophages, but the M2 polarization seems to dominate in tumors 
(Iachininoto et al., 2013; Minghetti, 2004; Nakanishi et al., 2011; Sharma et al., 2005; 
Tjiu et al., 2009). Macrophage recruitment and polarization in the tumor 
microenvironment has been shown to be impacted directly by glioblastoma cells through 
the STAT3 pathway (Wu et al., 2010). The STAT3 pathway is known to be impaired by 
indirubin, a natural compound isolated from the indigo plant, and synthetic indirubin 
derivatives to varying degrees (Li et al., 2011; Nam et al., 2005b; Zhang et al., 2011; 
Zhang et al., 2015; Zhou et al., 2009). 
Indirubin and indirubin derivatives have been shown to reduce angiogenesis, 
inflammation, and tumor progression (Blažević et al., 2015; Chan et al., 2012; Heshmati 
et al., 2013b; Ichimaru et al., 2015; Jakobs et al., 2005; Kim et al., 2011; Nam et al., 
2005a; Zhang et al., 2011; Zhang et al., 2015). Previous studies have shown the indirubin 
derivative indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) to possess 
immunomodulatory and anti-angiogenic properties (Anderson, 2014; Babcock et al., 
2013; Chan et al., 2012; Ichimaru et al., 2015; Nam et al., 2005a; Nam et al., 2012; 
Zhang et al., 2015). E804 has also been shown to block STAT3 signaling (Nam et al., 
2005b; Shin and Kim, 2012; Zhang et al., 2015). However, the effects of E804 on 
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angiogenesis and immunomodulation associated with glioblastoma have yet to be 
evaluated. Here, I show that E804 potent inducer of CYP1B1 in T98G cells, has modest 
effects on TGFβ2 secretion, and suppresses VEGF at high does, while enhancing VEGF 
secretion at low doses. However, E804 could also polarize macrophages to the pro-tumor 
M2 phenotype. The results of this study provide concerns with utilizing E804 as a 
treatment. The anti-angiogenic effects of E804 are promising, but the concentration 
would be difficult to achieve in vivo, and would need to be carefully monitored. 
However, if E804 enhances immune suppression within the tumor microenvironment, 
any anti-angiogenic effects may be lost or proven null. Further studies, particularly in 
vivo experiments, are needed, but use of E804 to reduce angiogenesis and tumor 
microenvironment immunosuppression in glioblastoma patients could be a viable option. 
 
MATERIALS AND METHODS 
Cells and Cell Culturing 
The human glioblastoma cell line T98-G (American Type Culture Collection, Manassas, 
Va.) was grown and maintained at 37°C with 5% CO2 in Corning 75 cm
2
 culture flasks, 
using Dulbecco's Modified Eagle Medium (DMEM, Cellgro) supplemented with 10% 
Fetal Calf Serum (FCS), 20 mM HEPES, 10 mM L-glutamine, 100 µg/ml penicillin, 100 
µg/ml streptomycin, 110 µg/ml sodium pyruvate, 1% non-essential amino acids (100x 
stock), and 4.5 g/L glucose. Previously published studies indicate an active AhR 
signaling pathway (Gramatzki et al., 2009a). 
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Human monocyte THP-1 (American Type Culture Collection, Manassas, Va.) cells were 
grown and maintained at 37°C with 5% CO2 in Corning 75 cm
2
 culture flasks using 
DMEM (Cellgro) supplemented with 10% FCS (Atlas; Fort Collins CO), 20 mM HEPES, 
10 mM L-glutamine, 100 µg/ml penicillin, 100 µg/ml streptomycin, 110 µg/ml sodium 
pyruvate, 1% non-essential amino acids (100x stock), 4.5 g/L glucose, and 1.5 g/L of 
NaCO3. To differentiate THP-1 cells to a macrophage phenotype, cells were pulsed with 
0.1 µM phorbol myristate acetate (PMA, Alexis Chemicals) for 72 hr (Daigneault et al., 
2010; Schwende et al., 1996). 
Mouse Hepa-1c1c7 cells are an AhR-active line commonly used for AhR activation and 
characterization studies (Bernhard et al., 1973; Hankinson, 1995; Hankinson et al., 1991). 
Cells were obtained from ATCC and maintained at 37°C with 5% CO2 in Corning 75 cm
2
 
culture flasks using DMEM (Cellgro) supplemented with 10% FCS (Atlas; Fort Collins 
CO), 20 mM HEPES, 10 mM L-glutamine, 100 µg/ml penicillin, 100 µg/ml 
streptomycin, 110 µg/ml sodium pyruvate, 1% non-essential amino acids (100x stock), 
4.5 g/L glucose, and 1.5 g/L of NaCO3.  
Chemicals 
The chemical structures of natural indirubin, E804, and TMZ are shown below in Figure 
2. Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804; Alexis Biochemical, San Diego 
CA) was solubilized in DMSO (Sigma Aldrich) to a stock solution of 10
-2
 M and stored 
at -20° C. Working dilutions were made with DMEM (supplemented as previously 
described) to final concentrations of 10 µM, 1 µM, and 0.1 µM. 10 µM Temozolomide 
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(TMZ; Tokyo Chemical Industry), the most common chemotherapeutic agent for 
glioblastoma, was also solubilized in DMSO, and brought to working concentration in 
DMEM, was used as a comparison to the activity of E804.  
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(a) (b)  (c)  
Figure 2: Chemical structures of (a) natural indirubin, (b) E804, (c) TMZ. 
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Cytotoxicity Assay 
Viability of the cells was quantified as a function of their succinate dehydrogenase 
activity, a measure of cellular respiration, by performing an MTT (3-[4,5-28 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Two treatment time points 
were analyzed: 6 and 24 hours. Each cell line was treated with 0.1, 1, or 10 µM E804 and 
a vehicle control of DMSO. Four hours prior to the end time point, 20 μl of a 5 mg/ml 
MTT solution in PBS was added to each well. At the end of the time point, wells were 
aspirated and 100 μl of acidified isopropanol (4 mM HCl, 0.1% Nondet P-40 (NP40) in 
isopropyl alcohol) were added to each well (Babcock et al., 2013). The plates were then 
shaken for 10 minutes to disrupt cells and dissolve any remaining formazan. The optical 
density of each well was then quantified at a wavelength of 550 λ. A positive control of 
tributyltin (TBT) was also tested (Kergosien and Rice, 1998). Data were recorded as 
optical densities and used to calculate cytotoxicity as a percentage of control treatments. 
Ki-67 Labeling Index 
As a secondary method to assess cell toxicity, the cellular proliferation marker Ki-67 was 
used as a means to determine labeling index (Louis et al.; Montine et al., 1994).  T98-G 
cells were seeded in 12-well plates, and incubated for 24 hours to allow adherence.  Cells 
were then treated, in triplicate, with 0.1, 1, and 10 µM E804 and a vehicle control of 
DMSO. At 12 and 24-hours post-treatment, media was aspirated from each well and the 
cells were fixed in 0.3% formalin in PBS buffer for 15 minutes at room temperature.  The 
fixative was then aspirated and PBS buffer added to the wells.  Cells were permeabilized 
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using 0.1% Triton-X in PBS for 30 minutes at room temperature.  The wells were then 
incubated with non-specific antibody blocking solution (10% FBS in PBS), washed x 3 in 
PBS with 0.5% tween-20 (PBS-T20), washed again x 3 with PBS-T20, then incubated 
mouse anti-Ki67 (mAb 4A1, 1:1000 in PBS) primary antibody (Thermo Fisher), and then 
goat anti-mouse secondary antibody conjugated with alkaline phosphatase (1:1000, 
Southern Biotech), each for 1 hour.  Alkaline phosphatase activity was detected using 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) in alkaline 
phosphatase buffer. The wells were then imaged and the number of stained cells out of 
the total number of cells were counted to establish a labeling index. 
CYP1B1 induction by E804 in T98G Cells 
Quantitative real time PCR was then performed to measure the expression levels of 
CYP1B1 following treatment with either 0.1, 1, or 10 µM E804, 10 µM DMSO carrier, 
or 10 µM Temozolomide (TMZ).  T98-G cells were seeded into 6-well plates and grown 
to near confluence, then exposed for 6, 12, and 24-hours. Overlying media from each 
well was aspirated, and cells were collected using 1 mL of RNAzol® (Molecular 
Research Center, Inc.). RNA was then isolated per the manufacturer’s instructions.  
cDNA was synthesized using qScript cDNA Supermix (Quanta) according to the 
manufacturer’s instructions.  Using primer sets listed in Table 1, qRT-PCR was 
performed using the SensiFAST™ SYBR® & Fluorescein kit (BioLine) according to the 
manufacturer’s instructions.  Each reaction was performed in triplicate. Plates were run 
and data was collected using the BioRad IQ5 detection system. Data were expressed as 
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fold increase in expression compared to GAPDH house-keeping gene expression using 
the Pfaffl method (Pfaffl, 2001).   
Effects of E804 on Growth Factor and Cytokine Secretion 
T98-G cells were grown to near confluence in T-150 flasks, then treated with either 0.1, 
1, or 10 µM E804, 10 µM DMSO carrier, or 10 µM Temozolomide (TMZ).  Supernatants 
and cells were collected at 24 and 48 hours post treatment, then frozen at -20ºC until 
ready for use.  Supernatants were then analyzed by commercially available human 
Cytokine Enzyme-linked Immunosorbent Assays (ELISA) kits (Biolegend, Thermo 
Fisher) for IL-6, TGF-β2, VEGF, and IL-10 per the manufacturer’s instructions. 
Effects of E804 on IDO1, TDO2, CYP1B1, and GAPDH Protein Expression 
At the time of supernatant collection described above, cells were lysed in 1 ml of RIPA 
lysis buffer (50 mM Tris HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, and 0.1% SDS) containing EDTA and protease inhibitor cocktail (Pierce) 
and transferred to snap cap tubes on ice for 30 minutes. Afterward, the tubes were 
vortexed again, then centrifuged at 12,000g for 10 minutes. The supernatant was then 
transferred to a new 1.5 ml tube, and its protein concentration quantified.  Protein 
samples were diluted to a common concentration so that equal concentrations were then 
run on a (4-20% SDS-PAGE) acrylamide gel, then transferred to PVDF blotting 
membrane for 1 hour on ice.  The PVDF blot was then incubated with non-specific 
antibody blocking solution overnight at 4ºC. The following day, the blocking solution 
was removed, and the PVDF blot was incubated with a targeted primary antibody for 1 
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hour with gentle shaking. Primary antibodies used were goat-anti-TDO2, rabbit-anti-
IDO1, rabbit-anti-CYP1B1, and goat-anti-GAPDH, each diluted 1:000 in PBS. The blot 
was the washed using PBS-T20 (0.05% Tween-20 in PBS buffer) 3 times for 5 minutes 
with vigorous shaking. The blot was then incubated with either goat anti-rabbit IgG-AP 
(1:000 in PBS, Southern Biotech) or rabbit anti-goat IgG-AP, depending on the origin 
species of the primary antibody. The blot was washed again as previously described, and 
alkaline phosphatase activity visualized with 5-bromo-4-chloro-3-indolyl-phosphate 
(BCIP) and nitro blue tetrazolium (NBT) in alkaline phosphatase buffer. Once fully 
developed, blots were rinsed with water and dried. Blots where then scanned and 
analyzed via ImageJ. 
Effects of Supernatants from Treated T98G Cells on Polarization of THP-1 Cells 
1x10
6
 THP-1 cells were seeded into 6-well plates and incubated for 72 hours with 0.1 µM 
tetradecanoyl phorbol acetate (PMA) to differentiate them into a macrophage lineage 
(Chanput et al., 2014; Garc  a et al., 1999).  Following differentiation and adherence, 
media was removed and cells were incubated for 24 hours with 50% dilution of 
supernatants from previously treated T98-G cells and fresh DMEM.  Each experiment 
was performed in triplicate. After incubation, cells were collected with 500 ul RNAzol 
and processed for RNA and cDNA for qRT-PCR as described above.  Genes of interest 
were IL-6, IL-10, Arginase1, Arginase2, IDO1, and COX-2, all of which were 
normalized against GAPDH.  See Table 1 for primers utilized. 
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Determining if T98G Supernatants Following Treatment Contain Residual AhR ligand 
Activity 
Hepa-1c1c7 cells were seeded into 6-well plates and grown to confluence. Cells were 
then incubated for 24 hours with a 1:1 mixture of supernatants from previously treated 
T98-G cells and fresh DMEM.  Cells were lysed and protein concentrations were 
quantified as previously described.  Protein levels of CYP1B1 and GAPDH were then 
measured by immunoblot as previously described. 
Statistical Analysis 
Comparisons of replicates were performed by ANOVA followed by Bonferroni's 
multiple contrast post-hoc tests using GraphPad Prism’s statistical software. An α value 
of 0.05 was established as statistically significant prior to experimentation (Fisher, 1946).  
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RESULTS 
MTT Assay 
The T98-G cells showed no significant decrease in cellular respiration as a result of 
treatment with up to 25 µM E804 for 6 or 24 hours (Figures 3 and 4).  Therefore, all 
studies continued to use E804 at concentrations of 0.1, 1, and 10 µM. 
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Figure 3: MTT Assay, 6-hour incubation 
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Figure 4: MTT Assay, 24-hour incubation 
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Ki-67 Labeling Index 
The protein Ki-67 is used as a marker of cellular proliferation. No significant difference 
was seen in the number of Ki-67 positive T98-G cells between the treatments of 0.1, 1, 
and 10 µM E804 and vehicle control of DMSO for 12 or 24 hours. Representative images 
of each time point are shown below (Fig 5). Ki-67 positive cells are dark purple, while 
negative cells appear clear.  
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Figure 5: T98-G cells labeled with Ki-67 
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CYP1B1 mRNA induction as a marker for AhR activity 
To determine the strength of interaction of E804 with the aryl hydrocarbon receptor, 
expression of CYP1B1, a downstream gene product of AhR activation, was measured via 
qRT-PCR. CYP1B1 expression was normalized against GAPDH. A dose and time-
dependent response was demonstrated. The highest CYP1B1 expression difference was 
seen in the 1 µM E804 treated cells, with a 5 to 10-fold change with respect to the DMSO 
vehicle control (Figure 6). 
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Figure 6: CYP1B1 mRNA expression in T98-G cells. Cells were treated with either 
DMSO vehicle control, 0.1 µM, 1 µM, or 10 µM E804 for 6, 12, or 24-hours. 
Corresponding letters above bars indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 
0.05, (c) P ≤ 0.0001, (d) P ≤ 0.01, (e) P ≤ 0.0001. 
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Cytokine ELISAs using T98-G Supernatants 
After treatment of T98-G cells with E804 and TMZ at 24 and 48 hours, the supernatants 
of T98-G cells were collected. ELISAs were performed using these supernatants to 
measure secretion of IL-6, TGF-β, VEGF, and IL-10. IL-6 secretion was significantly 
decreased as a result of 10 µM E804 at both 24 and 48 hours (Figure 7). TGF-β secretion 
was decreased at 24 hours, but increased at 48 hours at lower concentrations (Figure 8). 
VEGF secretion was increased at all concentrations of E804 except 10 µM, which 
significantly decreased expression (Figure 9). IL-10 secretion was not significantly 
impacted (Figure 10). Corresponding letters above bars indicate significance.  
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Figure 7: IL-6 secretion from T98-G cells. Cells were treated with DMSO vehicle 
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding 
letters above bars indicate a significant difference. (a) P ≤ 0.05, (b) P ≤ 0.01, (c) P ≤ 0.01, 
(d) P ≤ 0.05, (e) P ≤ 0.001, (f) P ≤ 0.001, (g) P ≤ 0.001, (h) P ≤ 0.01. 
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Figure 8: TGF-Beta secretion from T98-G cells. Cells were treated with DMSO vehicle 
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding 
letters above bars indicate a significant difference. (a) P ≤ 0.05. 
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Figure 9: VEGF secretion from T98-G cells. Cells were treated with DMSO vehicle 
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding 
letters above bars indicate a significant difference. (a) P ≤ 0.05, (b) P ≤ 0.01, (c) P ≤ 
0.0001, (d) P ≤ 0.05, (e) P ≤ 0.0001, (f) P ≤ 0.0001, (g) P ≤ 0.05, (h) P ≤ 0.05, (i) P ≤ 
0.0001, (j) P ≤ 0.0001, (k) P ≤ 0.0001, (l) P ≤ 0.0001, (m) P ≤ 0.001. 
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Figure 10: IL-10 secretion from T98-G cells. Cells were treated with DMSO vehicle 
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. No significant 
differences were seen. 
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Immunoblotting using T98-G Lysates 
T98-G cellular lysates were collected after E804 and TMZ treatment.  Western blots were 
performed probing for protein expression of IDO1, TDO2, CYP1B1, and GAPDH.  No 
induction was seen relative to the control for any of the proteins (data not shown). 
Expression of mRNAs indicative of M1 vs. M2 macrophage polarization 
T98-G cellular supernatants were collected after treatment as previously described, then 
applied to macrophage-like differentiated THP-1 cells for 24 hours. In this experiment, 
the 24 and 48 hour groups are with respect to the treatments of T98-G cells with E804. 
The mRNA expression of IL-6, Arginase 1 (ARG1), Arginase 2 (ARG2), IDO1, COX-2, 
and IL-10 were quantified and normalized against GAPDH. See Table 1 for primer sets 
utilized. IL-6 expression decreased in response to the 24-hour treated supernatants with 
respect to a media-only control, but significantly increased in response to the 48-hour 
supernatants treated with 0.1 µM E804. ARG1 expression decreased with respect to the 
media-only control in response to both the 24- and 48-hour treated supernatants. 
Alternatively, ARG2 expression generally increased in response to both groups. IL-10 
expression initially increased in response to the 24-hour treated supernatants, particularly 
the 10 µM, but decreased in response to the 48-hour treated supernatants. IDO1 
expression also generally increased in response to both groups. COX-2 expression 
decreased in response to the 24 hour DMSO vehicle control, 0.1, and 1 µM E804 treated 
supernatants and the 48 hour 1 µM E804 treated supernatant.  However, COX-2 
expression increased in response to the other treated supernatants. IL-10 expression 
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increased significantly in response to the 24- and 48-hour treated 10 µM E804 
supernatants.  
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Gene Primer Sequence (5' to 3') Anneal Temp (°C) Product Size (bp) 
GAPDH F: AGCCTCAAGATCATCAGCAATGCC 57 105 
 
R: TGTGGTCATGAGTCCTTCCACGAT 
  
    COX-2 F: TACTGGAAGCCAAGCACTTT 52 92 
 
R: GGACAGCCCTTCACGTTATT 
  
    IL-6 F: TCAATGAGGAGACTTGCCTGGTGA 58 123 
 
R: TACTCATCTGCACAGCTCTGGCTT 
  
    IL-10 F: TCCTTGCTGGAGGACTTTAAGGGT 57 109 
 
R: TGTCTGGGTCTTGGTTCTCAGCTT 
  
    ARG1 F: CAGGGCTACTCTCAGGATTAG 52 115 
 
R: CCGAAACAAGCCAAGGTTATT 
  
    ARG2 F: CATGGACAGCCAGTTTCATTTC 52 127 
 
R: CCACGTCTCTCAGACCAATATAC 
  
    IDO1 F: CACTTTGCTAAAGGCGCTGTTGGA 57 140 
 
R: GGTTGCCTTTCCAGCCAGACAAAT 
   
Table 1: qRT-PCR primer sets. 
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Figure 11: IL-6 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med 
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1 
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars 
indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.05, (c) P ≤ 0.05, (d) P ≤ 0.001, (e) 
P ≤ 0.01. 
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Figure 12: ARG1 mRNA expression in THP-1 cells. Cells were treated with DMEM 
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above 
bars indicate a significant difference. (a) P ≤ 0.05. 
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Figure 13: ARG2 mRNA expression in THP-1 cells. Cells were treated with DMEM 
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above 
bars indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.05, (c) P ≤ 0.05. 
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Figure 14: IDO1 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med 
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1 
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars 
indicate a significant difference. (a) P ≤ 0.05. 
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Figure 15: COX-2 mRNA expression in THP-1 cells. Cells were treated with DMEM 
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above 
bars indicate a significant difference. (a) P ≤ 0.05. 
 
42 
 
IL-10 mRNA Expression
IL
-1
0
 f
o
ld
 c
h
a
n
g
e
M
ed
 C
on
C
on 0.
1 1 10
TM
Z
C
on 0.
1 1 10
TM
Z
0
1
2
3
4
24 hour 48 hour
a
abc
b c d
de
e
 
Figure 16: IL-10 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med 
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1 
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars 
indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.001, (c) P ≤ 0.01, (d) P ≤ 0.05, (e) 
P ≤ 0.05. 
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Immunoblotting for CYP1B1 expression using Hepa-1c1c7 reporter cells 
T98-G cellular supernatants were collected after E804 and TMZ treatment, and then 
applied to Hepa-1c1c7 cells, which were incubated for 24 hours. Hepa-1c1c7 cellular 
lysates were then collected, and Western blots performed probing for CYP1B1 and 
GAPDH protein expression. No induction of CYP1B1 was seen (data not shown). 
 
DISCUSSION 
 In this study, I show that basal expression of IL-6, TGF-β, and VEGF T98G cells 
is extremely high, further supporting the notion that treating glioblastomas is difficult 
when they are already influencing local immune responses and angiogenesis at the time 
of diagnosis and first treatment. The secretion of IL-6, TGF-β, and VEGF could be 
reduced by 10 µM E804, and this reduction in cytokine and growth factor secretion could 
possibly lead to reduced angiogenesis. I also demonstrate that lower doses of E804 
enhanced the secretion of angiogenesis-inducing VEGF, which causes concern for even 
administering high doses of E804 because this indirubins in general are quickly 
metabolized and eliminated (Gillam et al., 2000), thus lowering local levels to the point 
of more VEGF secretion. Furthermore, E804 treatment increased the mRNA expression 
levels IL-6, IDO1, COX-2, and IL-10 in THP-1 macrophages, indicating an M2 
polarization. Thus, E804 may enhance immunosuppression in the tumor 
microenvironment. More studies are needed, but with careful monitoring, E804 could be 
a viable option to reduce angiogenesis and immunosuppression in glioblastoma patients. 
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Initial cytotoxicity studies using MTT showed that E804 treatment is not affecting 
cellular respiration, which is an indirect measurement of cell viability. Cells were also 
labeled with Ki-67, a marker of cellular proliferation (Louis et al.; Montine et al., 1994). 
After treatment, T98-G cells continued to proliferate, confirming the MTT data. 
Therefore, the E804 concentrations used experimentally were not cytotoxic. Previous 
studies from our lab have also shown E804’s lack of cytotoxicity on RAW264.7 murine 
macrophages (Anderson, 2014).  
 To measure if E804 is interacting with the aryl hydrocarbon receptor (AhR), I 
quantified CYP1B1 mRNA expression using qRT-PCR. The fold expression of CYP1B1 
increased in a time and dose-dependent manner with E804 treatment. This suggests that 
E804 is indeed interacting with the AhR and is being metabolized in the cell by the 
cytochrome p450 enzyme CYP1B1 (Denison and Nagy, 2003; Spink et al., 2003). Future 
studies should consider the possibility of incorporating AhR antagonist when using 
chemotherapeutic agents. 
Using the T98-G supernatants, ELISAs were performed to quantify IL-6, TGF-β, 
VEGF, and IL-10 secretion. Previous work from our lab has shown that LPS-stimulated 
RAW 264.7 macrophages secrete approximately 400 pg/ml of IL-6, so the fact that T98-
G glioma cells are producing around 600 pg/ml of IL-6 is considerable (Anderson, 2014). 
Heightened levels of IL-6 have been implicated in increased angiogenesis and tumor 
metastasis (Liu et al., 2010; Mauer et al., 2015; Taniguchi and Karin, 2014). This agrees 
with other studies that have shown the anti-angiogenic properties of E804 in human 
umbilical vein endothelial cells (Ali et al., 2005; Chan et al., 2012; Shin and Kim, 2012). 
45 
 
TGF-β secretion increased at 48 hours in response to lower concentrations of E804 and a 
slight reduction in TGF-β was seen in response to 10 µM E804 at both time points. TGF-
β has been shown to suppress T-cell function in tumor cells, and increase angiogenesis 
(Bodmer et al., 1989; Constam et al., 1992; Gramatzki et al., 2009b; Letterio, 1998; Wu 
et al., 2010). VEGF secretion was increased at all concentrations of E804 except 10 µM, 
which is cause for concern because VEGF is the main signal protein that initiates 
neovascularization, which is key for solid tumors to sustain growth (Ali et al., 2005; 
Byrne et al., 2005; Cabebe and Wakelee, 2007; Carmeliet, 2005; Kiselyov et al., 2007; 
Shibuya, 2006; Shin and Kim, 2012; Shinkaruk et al., 2003; Zhang et al., 2011). If high 
levels of E804 could be sustained, then local angiogenesis may be reduced.  
 The collected T98-G supernatants were also applied to differentiated macrophage-
like THP-1 cells.  Overall, the treated T98-G supernatants incubated with the THP-1 cells 
for 24 hours generally decreased IL-6 and ARG1 expression, and increased IDO1 
expression as compared to the media-only control. ARG2 and COX-2 expression did not 
significantly change. For the 48-hour group, there was a general decrease in ARG1 
expression, and an increase in IL-6, IDO1, ARG2, and COX-2 expression. An increase in 
IL-10 expression was seen as a result of the 10 µM E804 treated T98-G supernatants at 
both time points. Prior studies have identified increased ARG2 and IL-6 as M1 
macrophages markers, and ARG1, IDO1, and IL-10 as M2 macrophage markers (Bronte 
et al., 2003; Mantovani et al., 2002; Zea et al., 2005). COX-2 has been suggested as a 
marker for both M1 and M2 macrophages, but the M2 polarization seems to dominate in 
tumors (Nakanishi et al., 2011; Tjiu et al., 2009). It is difficult to tease apart individual 
46 
 
effects, since there is no doubt a balancing act involved in the expression of each gene, 
but with an increase in IL-6, IDO1, COX-2, and IL-10, the mRNA expression profile of 
THP-1 cells treated with T98-G supernatants suggests that there is a slight M2 
polarization occurring.  
To confirm that there was no biologically active E804 remaining in the treated 
T98-G supernatants, heap-1c1c cells were incubated with the supernatants and CYP1B1 
protein levels were measured via immunoblotting. No induction of CYP1B1 was seen, 
therefore, the supernatant’s effects seen on gene expression in the THP-1 qRT-PCR 
results are from factors secreted into the media by the T98-G cells, and not the presence 
of biologically active E804.  This observation bodes well for using potent, but labile AhR 
ligands as therapeutic agents in a variety of disease applications.   
The results of this study suggest the E804 could have anti-angiogenic properties at 
a concentration of 10 µM. However, it would be difficult to reach a concentration that 
high in vivo, except perhaps with a wafer implant, such as currently used with the 
chemotherapeutic drug carmustine (Gliadel®) (Perry, 2007). It is also worrisome that 
lower concentrations of E804 could potentially have the opposite effects, increasing 
cytokine production and angiogenesis. Another concern would be the slight M2 
polarization of macrophages seen in response to E804-treated T98-G supernatants. M2 
macrophages are pro-tumor and help suppress immune response the surrounding 
microenvironment (Kennedy et al., 2009; Kennedy et al., 2013; Mantovani et al., 2002; 
Wu et al., 2010). As a result, E804 may increase the immunosuppressive tumor 
environment, enhancing tumor survival and growth. Further characterization of the 
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effects of E804 is needed, particularly in vivo, but with controlled release or precise 
concentration monitoring, E804 has potential as a treatment option to reduce 
angiogenesis and immunosuppression in glioblastoma patients.  
 
FUTURE EXPERIMENTS 
 Moving forward, there are several in vitro experiments that would help clarify the 
mechanism by which E804 causes its effects. First, an experiment to knock-down or 
knock-out the aryl hydrocarbon receptor would definitively prove if E804’s action was 
mediated by this pathway. There are many ways to approach this type of experiment, but 
the most precise method would be to use the CRISPR/Cas9 system. Next, I would 
explore the nature of the immunomodulatory mechanism by which the T98-G 
supernatants act on the THP-1 differentiated macrophages. It would be interesting to see 
if the T98-G cells are releasing something other than cytokines and growth factors into 
the media, such as extracellular vesicles. To explore this question, I would compare the 
application of supernatants collected from T98-G cells to THP-1 cells to co-culturing 
T98-G cells with THP-1 differentiated macrophages. Another method would be to 
acquire bone-marrow derived macrophages, and use them in place of the differentiated 
THP-1 cells (Weischenfeldt and Porse, 2008). Finally, I would like to explore the effect 
of T98-G cells on the growth and migration of endothelial cells, such as human umbilical 
vein endothelial cells. For this experiment, I would also like to compare application of 
T98-G supernatants to endothelial cells with co-culturing of these two cell types.  
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After further in vitro characterization, I would move into an in vivo mouse model 
to compare to the in vitro results, in order to see if E804 could perform in a similar way 
in a live organism. To do this, I would want to first use an immunocompromised mouse 
model with a xenograft human glioma, such as U251 or U1242 MG, to look at 
angiogenesis, growth, and metastasis (Chen et al., 2013; Pontén, 1975; Zhao et al., 2010). 
To see the effect of E804 on immunomodulation in vivo, I would use adult mice or rats 
with an active immune system in which the formation of glioma-like tumors were 
initiated using a retrovirus, such as described in other studies (Assanah et al., 2006; 
Kamiyama et al., 2005; Kennedy et al., 2009; Uhrbom et al., 1998). 
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